Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03164889
- Locations
- 🇨🇳
302 Military Hospital, Beijing, Beijing, China
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 38
- Registration Number
- NCT03109730
- Locations
- 🇨🇳
Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
🇬🇧Royal London Hospital, London, United Kingdom
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03032536
- Locations
- 🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- ShuGuang Hospital
- Target Recruit Count
- 192
- Registration Number
- NCT02945956
- Locations
- 🇨🇳
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
🇨🇳Shanghai Zhongshan Hospital, Shanghai, China
A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 86
- Registration Number
- NCT02908191
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02881008
- Locations
- 🇷🇺
FSBI of Higher Education "People's Friendship University", Moscow, Russian Federation
🇷🇺SBIH "Stavropol Regional Clinical Hospital", Stavropol', Russian Federation
🇷🇺1-st MMU n.a. I.M. Sechenov based in Moscow State-Owned Health Care Institution "Infectious Clinical Hospital № 2 of Moscow Healthcare Department", Moscow, Russian Federation
Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT02849132
- Locations
- 🇨🇳
Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
- Conditions
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02797522
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02777801
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02777814
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.